Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Antibodies that block the immune inhibitory pathway of programmed death 1 (PD-1) protein have provided a major treatment advance in patients with cancer. In some patients with advanced non–small-cell lung cancer (NSCLC), these drugs unleash antitumor immunity, resulting in tumor regression and…

https://ift.tt/2vhVqWJ